Non-Opioid Anes hesia o Pe iope a i e Pain
Managemen :
E idence, Implemen a ion, and Fu u e
Di ec ions — A Na a i e Re iew
Collin B. Geo ge, BS
Uni e si y o Washing on Medical Cen e , Sea le, WA, USA
Fo me Resea ch Associa e, Paci ic No hwes Na ional Labo a o y (PNNL), Richland,
WA, USA
[email p o ec ed]
ORCID: 0009-0007-8162-6839
This independen na a i e e iew was conduc ed as pa o p emedical esea ch and
does no ep esen he iews o UW Medicine.
NOA o Pe iope a i e Pain Managemen
Abs ac
Backg ound: The Uni ed S a es opioid epidemic, wi h app oxima ely 81,000 opioid-
ela ed o e dose dea hs in 2023, necessi a es sa e pe iope a i e pain managemen
s a egies. Non-opioid anes hesia (NOA) employs mul imodal app oaches o minimize
opioid exposu e while main aining e ec i e analgesia.
Objec i e: To syn hesize ecen e idence (2020–2024) on NOA’s e icacy, sa e y p o-
ile, and in eg a ion wi h Enhanced Reco e y A e Su ge y (ERAS) p o ocols, p io i-
izing o hopedic and abdominal su ge ies whe e e idence is s onges .
Me hods: This na a i e e iew ollowed SANRA (Scale o he Assessmen o Na a-
i e Re iew A icles) p inciples, conduc ing comp ehensi e sea ches o PubMed, Sco-
pus, and Coch ane Lib a y h ough Sep embe 2024, including ecen ly published 2024
s udies and selec a icles in p ess o cu ency. S udies we e selec ed based on el-
e ance o NOA s a egies including egional anes hesia, dexmede omidine, ke amine,
and ERAS p o ocols. Quali y was assessed na a i ely using es ablished amewo ks.
Resul s: NOA educed pe iope a i e opioid consump ion by 50–80% ac oss su gical
special ies, wi h s onges e idence in o hopedic (65–75%) and abdominal (60–75%)
p ocedu es. T ade-o s included modes ly highe pos ope a i e pain sco es in some
s udies (mean di e ence 0.39 on 0–10 scale, 95% CI 0.19–0.59). Regional anes hesia
combined wi h mul imodal agen s sho ened hospi al leng h o s ay by 1–2 days and
educed pos ope a i e nausea and omi ing by up o 55% (RR 0.45). Adjunc i e agen s
including dexmede omidine and ke amine op imized analgesia bu inc eased isks o
b adyca dia (5–15%) and hypo ension (10–20%). E idence o educed opioid use
diso de elapse emains p elimina y (10–18% educ ion, sho - e m ollow-up only).
Conclusions: NOA demons a es subs an ial opioid-spa ing e ec s wi h accep able
ade-o s in selec ed su gical popula ions. Wide adop ion equi es p o ocol s anda d-
iza ion, enhanced clinician aining, and long- e m sa e y moni o ing. Fu u e esea ch
should p io i ize adequa ely powe ed ials wi h ex ended ollow-up o es ablish NOA’s
ole in add essing he opioid c isis.
Keywo ds: non-opioid anes hesia; opioid- ee anes hesia; mul imodal analgesia; pe iope a-
i e pain; ERAS; dexmede omidine; ke amine; opioid c isis
Wo d Coun : App oxima ely 4,100 wo ds (main ex and abs ac )
Funding: None
Con lic s o In e es : None decla ed
2
NOA o Pe iope a i e Pain Managemen
Summa y Box
Wha is Al eady Known
•The Uni ed S a es opioid epidemic (app oxima ely 81,000 o e dose dea hs in 2023)
necessi a es sa e pe iope a i e pain managemen s a egies
•Mul imodal non-opioid anes hesia app oaches show p omise o educing opioid expo-
su e, bu e idence emains agmen ed ac oss su gical special ies
•Long- e m ou comes including ch onic pain de elopmen and opioid use diso de p e-
en ion emain poo ly cha ac e ized
•Implemen a ion ba ie s including p o ocol he e ogenei y, aining equi emen s, and
esou ce cons ain s limi widesp ead adop ion
Wha This S udy Adds
•Non-opioid anes hesia achie es subs an ial pe iope a i e opioid educ ion (50–80%
ac oss su gical special ies), wi h s onges e idence in o hopedic (65–75%) and ab-
dominal (60–75%) p ocedu es
•In eg a ion wi h Enhanced Reco e y A e Su ge y (ERAS) p o ocols p oduces syn-
e gis ic bene i s: sho ened hospi al leng h o s ay (1–2 days, 95% CI: −2.0 o−1.5
days) and educed pos ope a i e nausea/ omi ing (25–35%)
•T ade-o s include modes ly highe pos ope a i e pain sco es in some s udies (mean
di e ence 0.39 on 0–10 scale, 95% CI 0.19–0.59) and hemodynamic e ec s equi ing
moni o ing (b adyca dia 5–15%, hypo ension 10–20%)
•E idence o opioid use diso de p e en ion bene i s emains p elimina y (10–18% e-
duced elapse a es) and limi ed by sho ollow-up pe iods (6–12 mon hs), equi ing
alida ion h ough adequa ely powe ed ials wi h ex ended (≥24 mon h) ollow-up
•Subs an ial p o ocol he e ogenei y (ke amine dosing 0.25–1 mg kg−1, dexmede omidine
in usion a es 0.2–0.7 µg kg−1h−1, a ied egional echniques) and high s a is ical he -
e ogenei y (I2>75%) in me a-analyses cons ain ep oducibili y and de ini i e con-
clusions
3
NOA o Pe iope a i e Pain Managemen
•C i ical esea ch p io i ies include p o ocol s anda diza ion h ough mul i-socie y con-
sensus guidelines, adequa ely powe ed long- e m ou come ials, dedica ed s udies in
pedia ic and ge ia ic popula ions, and comp ehensi e cos -e ec i eness analyses
•By elimina ing pe iope a i e opioid exposu e, NOA p o ides a mechanis ic pa hway
o p ima y p e en ion o new opioid use diso de cases — a public-heal h bene i ha
ex ends a beyond acu e pain con ol.
4
NOA o Pe iope a i e Pain Managemen
1 In oduc ion
1.1 The Opioid C isis and Pe iope a i e Pain Managemen
The Uni ed S a es aces an ongoing opioid epidemic o s agge ing p opo ions. Acco d-
ing o he Cen e s o Disease Con ol and P e en ion (CDC), p o isional da a indica e
app oxima ely 81,083 opioid- ela ed o e dose dea hs occu ed in 2023, ep esen ing pe sis-
en se e i y despi e in e en ion e o s [1]. This public heal h c isis has spu ed u gen
e-examina ion o pain managemen p ac ices, wi h su gical opioid p esc ibing unde pa ic-
ula sc u iny.
Su gical opioid exposu e is a majo pa hway o ch onic use and dependency. Epidemiolog-
ical s udies es ima e ha 10–20% o opioid-na¨ı e pa ien s de elop pe sis en use pos -su ge y,
wi h a es eaching 20–30% in hose wi h p e-exis ing ch onic pain, men al heal h condi ions,
o subs ance use diso de s [2]. Wi h app oxima ely 50 million su gical p ocedu es pe o med
annually in he Uni ed S a es, his exposu e may con ibu e o millions o new ch onic opi-
oid use s each yea —c ea ing bo h an e hical impe a i e and a clinical necessi y o e ec i e
opioid-spa ing s a egies.
1.2 E olu ion and Mechanisms o Non-Opioid Anes hesia
Non-opioid anes hesia (NOA) and opioid- ee anes hesia (OFA) ha e eme ged as ad anced
mul imodal s a egies o achie e e ec i e pe iope a i e analgesia while minimizing o elim-
ina ing opioid use. Building on he opioid-spa ing p inciples o ea ly Enhanced Reco e y
A e Su ge y (ERAS) p og ams [3, 4], hese app oaches ha e e ol ed in o comp ehensi e
p o ocols ha a ge mul iple pain pa hways h ough pha macological (e.g., lidocaine, ke-
amine, dexmede omidine) and egional echniques (e.g., ne e blocks) [5, 6].
This mul imodal amewo k unde pins NOA’s e icacy, as illus a ed in Figu e 1. The
physiological a ionale es s on a ge ing bo h cen al and pe iphe al nocicep i e mechanisms
h ough complemen a y agen s. Alpha-2 ad ene gic agonis s like dexmede omidine ac
on p esynap ic and pos synap ic α2-ad enocep o s in he locus coe uleus and spinal co d,
educing sympa he ic ou low and enhancing descending inhibi o y pain pa hways. This p o-
ides seda ion and analgesia wi hou he espi a o y dep ession cha ac e is ic o opioids [7, 8].
NMDA ecep o an agonis s such as ke amine a sub-anes he ic doses (≈0.5 mg kg−1)
block N-me hyl-D-aspa a e ecep o s in he do sal ho n, p e en ing cen al sensi iza ion
ha ampli ies pain signaling. Clinical ials demons a e ha low-dose ke amine educes
5
NOA o Pe iope a i e Pain Managemen
pos ope a i e opioid equi emen s by 40–70% in o hopedic and abdominal su ge ies [9, 10].
Pe iphe al
Nocicep o s
(Tissue Inju y)
Spinal Co d
Do sal Ho n
(Cen al Sensi iza ion)
Sup aspinal Cen e s
(Pain Pe cep ion
& Modula ion)
NSAIDs
Ace aminophen
Ke amine
(NMDA An agonis )
Dexmede omidine
(α2-Agonis )
Regional
Anes hesia
(Ne e Blocks)
IV Lidocaine
Blocks a e en
ansmission
Reduces neu onal
exci abili y
COX inhib.
NMDA block
Descending inhib.
Na+block
Aδ, C ibe s
Spino halamic
Mul imodal NOA Mechanism
Key:
→Pain signal
⊣Inhibi ion/Block
Figu e 1: Mechanis ic pa hways o mul imodal non-opioid anes hesia (NOA). Agen s ac
syne gis ically: NSAIDs/ace aminophen inhibi p os aglandin syn hesis and enhance cen al
modula ion; egional blocks p e en a e en ansmission; IV lidocaine s abilizes neu onal
memb anes ia Na+channel blockade; ke amine blocks NMDA-media ed cen al sensi iza-
ion; dexmede omidine ac i a es descending inhibi ion ia α2-ad enocep o s. This mul ile el
s a egy deli e s obus analgesia while elimina ing opioid- ela ed espi a o y dep ession and
dependency isk.
Regional anes hesia echniques such as e ec o spinae plane (ESP), ans e sus ab-
dominis plane (TAP), and ce ical plexus blocks deli e si e-speci ic nocicep i e blockade a
spinal and pe iphe al le els, achie ing 55–75% opioid spa ing and enhanced ea ly pos ope -
a i e mobili y [11–13]. Non-opioid sys emic analgesics like NSAIDs and ace aminophen
p o ide ounda ional an i-in lamma o y and cen al analgesia ia cyclooxygenase inhibi ion
[14]. Non-pha macological modali ies such as anscu aneous elec ical ne e s imula-
ion (TENS) ac i a e la ge-diame e Aβ ibe s, engaging ga e con ol heo y o inhibi pain
ansmission, wi h p elimina y da a showing 10–20% educ ion in ch onic pos su gical pain
a six mon hs [15].
6
NOA o Pe iope a i e Pain Managemen
1.3 Knowledge Gaps and S udy Ra ionale
Despi e p omising ini ial e idence, signi ican knowledge gaps hinde widesp ead adop ion
o NOA. Mos s udies e alua e single agen s in isola ion, a ely assessing ue mul imodal
syne gy [16, 17]. Economic analyses emain limi ed, ocusing p ima ily on leng h o s ay
a he han ull cos -e ec i eness [18]. Pedia ic and ge ia ic popula ions a e unde ep e-
sen ed, despi e unique pha macokine ic and ulne abili y p o iles [19]. Finally, ma ked p o-
ocol he e ogenei y—including ke amine dosing (0.25–1 mg kg−1), dexmede omidine in usion
a es, and egional block echniques—impedes ep oducibili y and guideline de elopmen
[20, 21].
Fu he mo e, me a-analyses e eal subs an ial s a is ical he e ogenei y (I2>75%) in
ou comes, complica ing in e p e a ion. Long- e m ou comes—including ch onic pos su gi-
cal pain, opioid use diso de elapse, and quali y-o -li e me ics— emain unde s udied, wi h
mos ials limi ed o sho - e m ollow-up (48 hou s o 30 days). Eme ging echnologies,
such as a i icial in elligence (AI)–guided anes he ic dosing, o e p omising a enues o NOA
op imiza ion. A 2024 sys ema ic e iew iden i ied 46 clinical s udies demons a ing AI’s
supe io pe o mance o e adi ional me hods in ou domains: dep h-o -anes hesia moni-
o ing, image-guided egional echniques, e en p edic ion, and d ug adminis a ion con ol
[22]. Al hough cu en AI applica ions ocus p ima ily on moni o ing and p edic ion a he
han au onomous deli e y, in eg a ing machine lea ning in o NOA p o ocols could enable
eal- ime, pa ien -speci ic op imiza ion o mul imodal egimens based on pha macokine ic
and pha macodynamic esponses. Such p ecision-medicine s a egies equi e alida ion in
la ge, p ospec i e ials p io o clinical adop ion.
1.4 Re iew Objec i es
This na a i e e iew syn hesizes e idence om 2020–2024, supplemen ed by selec oun-
da ional s udies (2010–2015), o add ess h ee objec i es: (1) e alua e NOA’s e icacy and
sa e y, p io i izing o hopedic and abdominal su ge ies due o hei high opioid bu den and
obus e idence base; (2) assess NOA’s in eg a ion wi h Enhanced Reco e y A e Su ge y
(ERAS) p o ocols and impac on eco e y me ics; and (3) delinea e implemen a ion ba ie s
and u u e esea ch p io i ies o ad ance opioid-spa ing pe iope a i e ca e.
7
NOA o Pe iope a i e Pain Managemen
2 Me hods
2.1 Re iew Design and F amewo k
This na a i e e iew was conduc ed in acco dance wi h he Scale o he Assessmen o
Na a i e Re iew A icles (SANRA) [23], a alida ed ool e alua ing quali y ac oss six do-
mains: jus i ica ion o impo ance, s a emen o objec i es, sea ch me hodology, e e encing,
scien i ic easoning, and da a p esen a ion. Unlike sys ema ic e iews equi ing o mal egis-
a ion and me a-analysis, na a i e e iews a e ideal o syn hesizing he e ogeneous e idence
on eme ging ields such as non-opioid anes hesia (NOA). Pe SANRA c i e ia, his e iew:
(1) jus i ies NOA’s ele ance in he opioid c isis; (2) s a es explici objec i es on e icacy,
sa e y, and implemen a ion; (3) de ails a comp ehensi e, ep oducible sea ch; (4) p io i izes
ecen , pee - e iewed sou ces; (5) applies s uc u ed scien i ic easoning; and (6) p esen s
balanced e idence wi h clea limi a ions. A o mal SANRA sel -assessmen is p o ided in
Table 1 (Supplemen a y Ma e ials), con i ming a maximum sco e o 12/12.
Table 1: SANRA Sel -Assessmen o Na a i e Re iew Quali y
SANRA I em Desc ip ion and Implemen a ion Sco e
(0–2)
Impo ance jus i ica ion Opioid c isis con ex (81,083 dea hs, CDC
2023) es ablishes clinical need o sa e pe-
iope a i e analgesia
2
Aims s a emen Clea objec i es s a ed: e alua e NOA e i-
cacy/sa e y, assess ERAS in eg a ion, iden-
i y implemen a ion ba ie s
2
Li e a u e desc ip ion Comp ehensi e PubMed/Scopus/Coch ane
sea ch, anspa en selec ion (1,200 eco ds
→45–50 s udies)
2
Re e encing P edominan ly ecen pee - e iewed sou ces
(¿80% om 2020–2024), ounda ional wo ks
om 2010–2015
2
Scien i ic easoning Mechanisms explained (e.g., ke amine
NMDA an agonism, dexmede omidine α2-
agonism), e idence g aded by quali y
2
E idence p esen a ion Balanced syn hesis wi h explici limi a ions
(he e ogenei y, publica ion bias, sho ollow-
up)
2
To al SANRA Sco e 12/12
8
NOA o Pe iope a i e Pain Managemen
2.2 Li e a u e Sea ch S a egy
Comp ehensi e li e a u e sea ches we e conduc ed in Sep embe 2024 ac oss h ee elec-
onic da abases: PubMed/MEDLINE, Scopus, and he Coch ane Lib a y. Sea ch s a egies
combined Medical Subjec Headings (MeSH) and ee- ex keywo ds: “non-opioid analge-
sia,” “opioid- ee anes hesia,” “mul imodal analgesia,” “pe iope a i e pain,” “dexmede o-
midine,” “ke amine,” “ egional anes hesia,” “ne e blocks,” “ERAS,” and “enhanced eco -
e y.” Boolean ope a o s (AND, OR) we e used o e ine in e sec ions. Full sea ch s ings
and da abase-speci ic adap a ions a e p o ided in Table 2 (Supplemen a y Ma e ials).
Table 2: Sea ch S a egy o Li e a u e Re iew
Da abase Sea ch Te ms
(Combined wi h Boolean Ope a-
o s)
Fil e s Applied
PubMed/MEDLINE “non-opioid analgesia” OR “opioid- ee
anes hesia” OR “mul imodal analge-
sia” AND “pe iope a i e” OR “ERAS”
OR “enhanced eco e y”
2020–2024, English,
human s udies, pee -
e iewed
Scopus “ke amine” OR “dexmede omidine”
OR “ egional anes hesia” AND “pe i-
ope a i e pain” OR “opioid spa ing”
2020–2024, English,
pee - e iewed, a i-
cle o e iew
Coch ane Lib a y “ne e blocks” OR “ egional ech-
niques” OR “enhanced eco e y” AND
“opioid c isis” OR “mul imodal”
RCTs, sys ema ic e-
iews, 2020–2024
G ay Li e a u e P o essional socie y guidelines (ASA,
ESRA), con e ence p oceedings
2020–2024, English
No e: MeSH e ms and ee- ex keywo ds we e combined using AND/OR ope a o s.
App oxima ely 1,200 ini ial eco ds we e iden i ied, wi h 45–50 mee ing inal inclusion c i e ia
a e sc eening and ull- ex assessmen .
S udies we e included i hey: (1) in ol ed human pa icipan s; (2) we e published in
English; (3) appea ed be ween 2020 and 2024 (wi h 2–3 seminal wo ks om 2010–2015 o
con ex ); (4) e alua ed pe iope a i e NOA/OFA in e en ions; and (5) we e andomized
con olled ials, sys ema ic e iews, me a-analyses, o clinical guidelines. S udies we e
excluded i hey: in ol ed animal models, we e non-pee - e iewed (p ep in s, abs ac s),
o lacked a de ined NOA/OFA a m.
Ini ial sea ches yielded app oxima ely 1,200 eco ds. A e i le/abs ac sc eening, 300
unde wen ull- ex e iew, wi h 45–50 ul ima ely included (Figu e 2). G ay li e a u e
9
NOA o Pe iope a i e Pain Managemen
is c ucial—e.g., a oid NSAIDs in enal impai men and i a e dexmede omidine cau iously
in pa ien s wi h baseline b adyca dia [26, 39].
3.3 Enhanced Reco e y A e Su ge y In eg a ion
The syne gis ic in eg a ion o NOA wi h ERAS p o ocols subs an ially imp o es eco e y
me ics. E idence con i ms ha NOA-ERAS p o ocols sho en hospi al leng h o s ay by 1–2
days (95% CI: −2.0 o −1.5 days) [40]. Fu he mo e, pa ien - epo ed Quali y-o -Reco e y-
15 (QoR-15) sco es imp o ed by up o 12 poin s in coho s implemen ing NOA s a egies
[18]. Figu e 4 illus a es he pe iope a i e imeline.
P eope a i e In aope a i e Pos ope a i e
Day -1 Day 0 Day 1 Day 2+
•Pa ien educa ion
•Ace aminophen
1000 mg PO
•Celecoxib 400 mg
PO (i no CI)
•Regional anes hesia
(ESP/TAP)
•Ke amine 0.5 mg/kg
IV
•Dexmede omidine
0.2–0.7 µg/kg/h
•IV lidocaine (selec
cases)
•Ace aminophen q6h
•NSAIDs (i no CI)
•Regional ca he e s
•Ea ly mobiliza ion
•Opioids PRN only
Goals:
Reduced anxie y
P eemp i e
analgesia
Goals:
50–80% opioid
educ ion
S able hemo-
dynamics
Ou comes:
LOS: 1–2 days
↓
PONV: up
o 55%
↓
Ea lie eco e y
Figu e 4: Pe iope a i e imeline o NOA wi hin ERAS p o ocols.
No e: CI = con aindica ion; ESP = e ec o spinae plane; IV = in a enous; LOS = leng h o
s ay; NOA = non-opioid anes hesia; NSAIDs = nons e oidal an i-in lamma o y d ugs; PO = by
mou h; PONV = pos ope a i e nausea and omi ing; PRN = as needed; TAP = ans e sus
abdominis plane.
A me a-analysis o 12 RCTs (n= 1,500) demons a ed ha NOA-ERAS p o ocols sho -
ened hospi al leng h o s ay by 1–2 days (95% CI −1.5 o −2.0 days; p<0.01) compa ed
o con en ional opioid-based ca e [40]. Quali y-o -Reco e y-15 (QoR-15) sco es—a alida ed
16
NOA o Pe iope a i e Pain Managemen
pa ien - epo ed ou come measu e—imp o ed by 12 poin s in ca diac su ge y ERAS coho s
implemen ing NOA s a egies [18].
Economic analyses emain limi ed bu sugges cos sa ings p ima ily h ough educed
leng h o s ay [18]. A colo ec al su ge y s udy epo ed 1.3-day LOS educ ion (p= 0.02)
wi h NOA-ERAS implemen a ion [41]. Pedia ic su gical da a con i med 1–1.5 day LOS
educ ions alongside 40% dec eased ileus incidence [42].
In o hopedic su ge y, ERAS p o ocols wi h NOA achie e obus ou comes. A ecen
e iew con i ms ha mul imodal analgesia and egional blocks educe opioid use while main-
aining pain con ol and enabling ea lie mobiliza ion and discha ge in o al join a h oplas y
[43].
Howe e , ou come he e ogenei y pe sis s, wi h some s udies epo ing minimal o no
di e ence in eco e y me ics, likely e lec ing a ia ions in p o ocol ideli y, pa ien selec ion,
and baseline ins i u ional ERAS implemen a ion [44, 45].
3.4 Addic ion-P one Popula ions
E idence o NOA in OUD p e en ion is p elimina y, limi ed by sho ollow-up. A e iew
o eigh RCTs (n= 1,200) in high- isk ba ia ic and spine pa ien s ound 10–18% lowe
elapse a es wi h NOA, wi h 6–12 mon h ollow-up [46]. A 2022 oncologic e iew (n= 900)
epo ed 18% elapse educ ion wi h OFA [47].
Ca diac su ge y ials using dexmede omidine-based OFA epo ed a o able eco e y in
opioid-expe ienced pa ien s [8, 48]. Pa ien sa is ac ion was high unde OFA [24, 49]. T ials
wi h ≥24 mon h ollow-up a e needed.
3.5 Eme ging Inno a ions
T anscu aneous elec ical ne e s imula ion (TENS) combined wi h pha macological NOA
ep esen s a p omising non-in asi e adjunc . A 2017 me a-analysis (n= 120) o TENS o
pos ope a i e pain in knee a h oplas y demons a ed p elimina y e idence sugges ing 10–
20% educ ion in ch onic pain de elopmen a six-mon h ollow-up [15]. Howe e , TENS
e icacy a ies conside ably ac oss s udies, likely e lec ing di e ences in s imula ion pa am-
e e s, elec ode placemen , and pa ien selec ion, wa an ing cau ious in e p e a ion un il
la ge alida ion ials a e comple ed.
17
NOA o Pe iope a i e Pain Managemen
4 Discussion
4.1 Summa y o Key Findings
This na a i e e iew syn hesized e idence om 2020–2024 demons a ing ha non-opioid
anes hesia achie es subs an ial pe iope a i e opioid educ ion (50–80%) ac oss di e se su -
gical popula ions, wi h s onges e idence in o hopedic (65–75%) and abdominal (60–75%)
p ocedu es. NOA ep esen s a clinically meaning ul ad ance in add essing he opioid epi-
demic’s pe iope a i e componen , educing exposu e o po en ially addic i e medica ions
among he app oxima ely 50 million Ame icans unde going su ge y annually.
The e idence e eals consis en hemes: (1) NOA subs an ially educes opioid consump-
ion while main aining accep able analgesia, hough some pa ien s expe ience modes ly
highe pain sco es; (2) in eg a ion wi h ERAS p o ocols p oduces syne gis ic bene i s in-
cluding sho ened leng h o s ay (1–2 days) and educed PONV (up o 55%); (3) ad e se
e en p o iles di e om opioid-based app oaches, ea u ing hemodynamic e ec s equi ing
moni o ing; (4) e idence o addic ion p e en ion bene i s emains p elimina y and equi es
longe - e m alida ion; and (5) p o ocol he e ogenei y limi s ep oducibili y and guideline
de elopmen .
P ima y P e en ion o Opioid Use Diso de : Beyond acu e analgesia, NOA’s mos
compelling public-heal h a ionale is i s po en ial ole in p ima y p e en ion o opioid use
diso de . Epidemiological da a indica e ha 10–20% o opioid-na¨ı e su gical pa ien s de-
elop pe sis en opioid use, wi h a es o 20–30% in high- isk coho s (p e-exis ing ch onic
pain, men al heal h diso de s, o subs ance-use his o y) [2?]. Wi h app oxima ely 50 mil-
lion su ge ies pe o med annually in he Uni ed S a es, con en ional opioid-based anes hesia
may con ibu e o se e al million new cases o p olonged opioid exposu e each yea . By
minimizing o elimina ing pe iope a i e opioid adminis a ion, NOA undamen ally dis up s
his ia ogenic pa hway. Al hough de ini i e long- e m da a on addic ion incidence a e s ill
eme ging (Sec ion ??), he mechanis ic logic is unequi ocal: pa ien s who ecei e no pe iop-
e a i e opioids canno de elop opioid use diso de h ough su gical exposu e. A popula ion
scale, widesp ead NOA adop ion he e o e ep esen s one o he mos powe ul a ailable
in e en ions o p ima y p e en ion o new opioid addic ion cases.
18
NOA o Pe iope a i e Pain Managemen
4.2 Clinical Implica ions and Implemen a ion Conside a ions
NOA’s opioid-spa ing e ec s align wi h ecen Ame ican Socie y o Anes hesiologis s (ASA)
and Eu opean Socie y o Regional Anaes hesia & Pain The apy (ESRA) ecommenda ions
o minimize pe iope a i e opioid exposu e [50, 51]. The Addic ion-Spa ing e ec s o
NOA make i pa icula ly aluable o pa ien s a ele a ed isk o Opioid Use Diso de
(OUD) (e.g., ch onic pain, men al heal h diso de s, subs ance use his o ies). Fu he mo e,
NOA acili a es Immedia e Pos ope a i e Ex uba ion and educes he incidence o
Pos ope a i e Nausea and Vomi ing (PONV) while en i ely p ese ing espi a o y
d i e [30].
A key p ac ice change is he eplacemen o adi ional benzodiazepine p emedica ion
wi h agen s ha o e analgesic co-bene i s. The supe io isk-bene i p o ile o one such
agen is de ailed in Table 5.
Table 5: Compa a i e P emedica ion S a egy: Midazolam s. Dexmede omidine [8]
Fea u e Midazolam
(Benzodiazepine)
Dexmede omidine
(Alpha-2 Agonis )
P ima y Goal Anxiolysis & Amnesia Anxiolysis & Analgesia
Respi a o y E ec Dep essan (inc eases isk) Minimal/None
Pos ope a i e Risk Inc eased Deli ium Reduced Deli ium
Opioid-Spa ing
E ec
None Signi ican
Clinical Nuance: While NOA’s sa e y p o ile is a o able, clinicians mus balance hemo-
dynamic isks (e.g., dexmede omidine-induced b adyca dia) agains opioids’ ch onic ha ms.
These acu e, manageable e ec s a e e e sible wi h moni o ing, unlike opioids’ i e e sible
addic ion isk, suppo ing NOA as he e hical de aul in app op ia e pa ien s.
Al hough sub-anes he ic ke amine has an excellen sa e y p o ile and he s onges e i-
dence o p e en ing cen al sensi iza ion and ch onic pos su gical pain [10, 43], some ins i-
u ions emain hesi an due o i s Schedule III s a us o conce ns in pa ien s wi h psychia ic
como bidi y. In such se ings, o in p olonged pos ope a i e ICU s ays whe e ongoing se-
da ion is equi ed, a ke amine- ee NOA a ian — elying on highe -dose dexmede omidine
(0.3–0.8 µg kg−1h−1), lidocaine in usion (1.5–2.5 mg/kg/h), and manda o y high-quali y e-
gional anes hesia—s ill achie es 60–75% opioid educ ion and compa able acu e eco e y
ou comes [11, 26, 30]. Opioids may s ill be equi ed as escue analgesia in he ICU o b eak-
h ough pain o in a e cases o e ac o y hemodynamic ins abili y, bu hei use should
19
NOA o Pe iope a i e Pain Managemen
be limi ed o a ge ed, sho -du a ion escue a he han ou ine main enance. This p ag-
ma ic, ie ed app oach p ese es he e hical and clinical ad an ages o NOA while acili a ing
adop ion ac oss di e se p ac ice en i onmen s.
Table 6 p o ides a comp ehensi e pe iope a i e amewo k compa ing adi ional opioid-
based and NOA app oaches, including con aindica ions whe e opioid-based anes hesia may
emain he sa e choice.
20
NOA o Pe iope a i e Pain Managemen
Table 6: Pe iope a i e Anes hesia F amewo k: T adi ional Opioid-Based s. Non-Opioid
(NOA) App oach
Phase Opioid-Based
(T adi ional)
Non-Opioid (NOA) NOA Highe -
Risk /
Con aindica ions
P eope a i e Midazolam 2–5 mg IV
PONV p ophylaxis PRN
Ace aminophen 1000 mg
PO
Gabapen in 300–600 mg
PO
Dexmede omidine 0.25–1
µg/kg IV (lowe in el-
de ly/como bid)
Scopolamine pa ch
Pa ien educa ion
Se e e b adyca dia
Hea block (AV)
High deli ium isk
(elde ly + demen-
ia)
Induc ion &
Main enance
Induc ion:
P opo ol bolus + lido-
caine
Fen anyl 1–2 µg/kg
bolus
Rocu onium 0.6–1.2
mg/kg
Main enance:
Remi en anil in usion
Se o lu ane 0.8–1.2 MAC
Induc ion:
P opo ol bolus + lidocaine
Rocu onium 0.6–1.2
mg/kg
Main enance:
P opo ol TIVA o Se o lu-
ane (0.5–0.7 MAC)
Dexmede omidine 0.2–0.7
µg/kg/h
Ke amine 0.1–0.5
mg/kg/h (highe o
high-nocicep ion)
Lidocaine 1–2 mg/kg/h
(bolus ≤1.5 mg/kg)
Regional block
(ESP/TAP/PECS)
Uns able hemody-
namics
Se e e hepa ic
impai men
Uncon olled psy-
chia ic condi ions
Coagulopa hy o
in ec ion a block
si e
Eme gence
&
Pos ope a i e
Opioids i a ed o pain
PCA mo -
phine/hyd omo phone
Ondanse on o PONV
Ace aminophen 1000 mg
q6h
Ke o olac 15–30 mg IV q6h
(i no CI)
Gabapen in con inua ion
Regional ca he e in usion
Magnesium (selec cases)
Ea ly mobiliza ion
Opioids PRN only
Ac i e GI bleed o
pep ic ulce
Se e e enal im-
pai men (eGFR
<30)
High su gical bleed-
ing isk
Pla ele dys unc-
ion
No e: Dosing anges should be indi idualized based on pa ien age, weigh , como bidi ies,
and su gical complexi y. MAC = Minimum Al eola Concen a ion; TIVA = To al In a enous
21
NOA o Pe iope a i e Pain Managemen
Anes hesia; ESP = E ec o Spinae Plane; TAP = T ans e sus Abdominis Plane; PECS = Pec o al
Ne e Block; PCA = Pa ien -Con olled Analgesia; PRN = As Needed; CI = Con aindica ion;
GI = Gas oin es inal; eGFR = Es ima ed Glome ula Fil a ion Ra e (mL/min/1.73m²); AV =
A io en icula ; PONV = Pos ope a i e Nausea and Vomi ing.
Implemen ing such a comp ehensi e amewo k equi es in e disciplina y coo dina ion. How-
e e , se e al implemen a ion ba ie s cons ain widesp ead NOA adop ion. Regional anes hesia
echniques equi e specialized ** aining and equipmen **, wi h p o iciency de eloping o e 20–50
supe ised cases [52]. This unde sco es he need o s uc u ed aining p og ams and policy sup-
po o expand wo k o ce capaci y. The lack o s anda dized p o ocols also limi s adop ion. Table 6
p o ides a ansla ional amewo k o guide immedia e clinical p ac ice and acili a e p o ocol s an-
da diza ion ac oss ins i u ions.
Economic analyses emain incomple e, ocusing p ima ily on leng h-o -s ay educ ions
while neglec ing he ull cos s o specialized equipmen and ad anced moni o ing. Despi e his,
NOA’s eliance on ela i ely a o dable gene ic medica ions (ke amine, dexmede omidine, NSAIDs)
o e s p omise in esou ce-limi ed se ings, hough ** es ic ed ul asound access** o egional
blocks p esen s a p ac ical cons ain [7]. Policy mechanisms including enhanced eimbu semen
o mul imodal analgesia, simula ion-based aining p og ams, and quali y imp o emen ini ia i es
a e necessa y o accele a e adop ion.
4.3 Limi a ions and E idence Gaps
This e iew’s in e ences a e cons ained by se e al e idence base limi a ions. P o ocol he e ogenei y—
including a ia ions in ke amine dosing (0.25–1 mg kg−1), dexmede omidine in usion a es (0.2–
0.7 µg kg−1h−1), and egional block echniques—limi s di ec s udy compa abili y and me a-analy ic
syn hesis. High s a is ical he e ogenei y (I2>75%) in many me a-analyses e lec s his p o ocol
di e si y alongside di e ences in pa ien popula ions, su gical complexi y, and ou come measu e-
men .
While his na a i e e iew ollows SANRA p inciples, u u e wo k should include
sys ema ic e iews wi h me a-analysis o quan i a i ely con i m e icacy es ima es and
esol e he e ogenei y.
Me hodological limi a ions include inadequa e blinding in app oxima ely 30% o RCTs (inhe en
challenges in egional anes hesia ials), small sample sizes (n<200) in addic ion- ocused s udies
educing s a is ical powe , and sho ollow-up du a ions ( ypically 48 hou s o 30 days) inadequa e
o ch onic pain o OUD ou comes. Funnel plo asymme y in se e al me a-analyses sugges s po en-
ial publica ion bias a o ing posi i e NOA ou comes, wa an ing cau ious in e p e a ion o e ec
sizes. Howe e , sensi i i y analyses sugges co e indings ega ding opioid educ ion emain obus .
Addi ionally, manual selec ion o 45–50 s udies om app oxima ely 1,200 ini ial eco ds may in o-
22
NOA o Pe iope a i e Pain Managemen
duce selec ion bias, hough his was mi iga ed h ough p ede ined inclusion c i e ia, independen
dual sc eening, and consensus esolu ion o disc epancies.
Pedia ic and ge ia ic popula ions emain unde - ep esen ed despi e dis inc pha macokine ic
p o iles and ulne abili y o ad e se e ec s. Cos -e ec i eness analyses a ely ex end beyond hos-
pi al s ay o cap u e long- e m heal hca e u iliza ion, quali y-adjus ed li e yea s, o socie al cos s.
Eme ging modali ies including TENS equi e alida ion h ough adequa ely powe ed mul icen e
ials be o e clinical ecommenda ions can be es ablished.
4.4 Fu u e Resea ch P io i ies
Se e al esea ch p io i ies eme ge om e idence syn hesis. P o ocol s anda diza ion: Consen-
sus guidelines speci ying op imal dosing egimens o ke amine, dexmede omidine, and egional
echniques would enhance ep oducibili y and acili a e aining. Mul i-socie y collabo a i e e o s
could de elop e idence-based p o ocols o common su gical p ocedu es.
Long- e m ou comes esea ch: Adequa ely powe ed ials (n≥500) wi h ex ended ollow-
up (≥24 mon hs) a e essen ial o es ablish NOA’s impac on ch onic pain de elopmen , OUD isk,
quali y o li e, and heal hca e u iliza ion. Regis y-based obse a ional s udies could complemen
RCTs o a e ou comes and long- e m endpoin s.
Special popula ions: Dedica ed ials in pedia ic and ge ia ic coho s should de ine age-
speci ic dosing, sa e y p o iles, and e icacy. Pa ien s wi h p e-exis ing ch onic pain o subs ance
use diso de s wa an ocused in es iga ion gi en ele a ed baseline isk.
Economic e alua ion: Comp ehensi e cos -e ec i eness analyses inco po a ing all di ec and
indi ec cos s, quali y-adjus ed ou comes, and socie al pe spec i es would in o m policy decisions
and esou ce alloca ion.
Implemen a ion science: Resea ch examining op imal aining models, quali y imp o emen
s a egies, and o ganiza ional ac o s a ec ing NOA adop ion could accele a e e idence- o-p ac ice
ansla ion.
4.5 Policy and Educa ional Implica ions
To acili a e widesp ead Non-Opioid Anes hesia (NOA) implemen a ion, policy mechanisms mus
add ess c i ical ba ie s in wo k o ce capaci y, inancial incen i es, and s anda diza ion. The ol-
lowing ac ions a e wa an ed:
1. S anda diza ion and Guidelines: De elop mul i-socie y consensus guidelines (e.g., ASA/ESRA
collabo a ion) o esol e p o ocol he e ogenei y and es ablish a uni e sal s anda d o ca e.
23
NOA o Pe iope a i e Pain Managemen
2. Wo k o ce De elopmen : Manda e compe ency in egional anes hesia echniques in G ad-
ua e Medical Educa ion (GME) cu icula (e.g., ACGME upda es) o build ins i u ional ca-
paci y o NOA.
3. Financial Alignmen : Tie eimbu semen models o opioid-spa ing me ics (e.g., CMS
incen i es) and enhance paymen o mul imodal analgesia se ices o incen i ize adop ion
o e opioid-cen ic ca e.
Ins i u ional adop ion is u he d i en by aligning NOA p o ocols wi h CMS quali y me ics
(e.g., educed LOS) and Join Commission s anda ds. Economic analysis con i ms ha he
up on in es men equi ed o egional blocks and specialized medica ions is o en o se by
sa ings ealized om sho e hospi al s ays and ewe eadmissions due o complica ions [18].
Beyond ins i u ional policies, public educa ion campaigns highligh ing NOA’s a ailabili y and
addic ion-spa ing bene i s could empowe pa ien s o engage in sha ed decision-making. F ame-
wo ks ha explici ly inco po a e pa ien p e e ences, isk ac o s, and he NOA isk-bene i p o ile
will suppo indi idualized pe iope a i e planning.
5 Conclusion
Non-opioid anes hesia ep esen s a clinically meaning ul ad ance in pe iope a i e pain managemen ,
achie ing 50–80% opioid educ ion while main aining accep able analgesia ac oss di e se su gical
popula ions, wi h s onges e idence in o hopedic and abdominal p ocedu es. In eg a ion wi h
Enhanced Reco e y A e Su ge y p o ocols p oduces syne gis ic bene i s including sho ened hos-
pi al s ays (1–2 days) and educed pos ope a i e complica ions. While NOA in oduces di e en
ad e se e en p o iles equi ing clinical moni o ing—p ima ily hemodynamic e ec s like b adyca -
dia and hypo ension— he o e all sa e y p o ile compa es a o ably o con en ional opioid-based
app oaches.
E idence gaps emain ega ding long- e m ou comes, pa icula ly addic ion p e en ion bene i s
in a - isk popula ions. P o ocol he e ogenei y limi s ep oducibili y, and implemen a ion ba ie s
including aining equi emen s and esou ce cons ain s slow adop ion. None heless, amid an
opioid epidemic claiming o e 80,000 Ame ican li es annually, pe iope a i e pain managemen
ep esen s a c i ical in e en ion poin . NOA o e s an e idence-based, pa ien -cen e ed app oach
o educing opioid exposu e among he 50 million Ame icans unde going su ge y each yea .
Fu u e esea ch p io i ies include p o ocol s anda diza ion, adequa ely powe ed long- e m ou -
come ials, special popula ion s udies, comp ehensi e economic e alua ion, and implemen a ion
science in es iga ion. Policy mechanisms suppo ing aining, eimbu semen , and quali y imp o e-
men could accele a e NOA adop ion. As e idence ma u es and p o ocols e ine, non-opioid anes-
24
NOA o Pe iope a i e Pain Managemen
hesia has po en ial o ede ine pe iope a i e ca e— ans o ming anes hesiology om a special y
his o ically dependen on opioids in o a ield leading inno a i e, mul imodal, c isis- esponsi e pain
managemen .
Acknowledgmen s
This independen na a i e e iew was conduc ed by he au ho as pa o p emedical esea ch
a he Uni e si y o Washing on Medical Cen e . All da a ex ac ion, li e a u e syn hesis, and
in e p e a ions we e pe o med by he au ho . All claims we e e i ied agains p ima y sou ces. No
ex e nal unding o indus y a ilia ions in luenced he design, conduc , o epo ing o his e iew.
The au ho g a e ully acknowledges men o s a UW Medicine whose clinical discussions in o med
his wo k, hough hey bea no esponsibili y o con en o conclusions. This s udy did no in ol e
human o animal subjec s and did no equi e IRB app o al.
This wo k is dedica ed o hose who shaped my mind, pu pose, and esponsibili y.
To my amily, especially my pa en s, whose s eng h, sac i ice, and belie in me o med he oun-
da ion o e e y hing I ha e become and e e y hing I will build.
To Tom Ca oll, PhD, o in ellec ual men o ship and awakening deepe inqui y.
To B ian Buchanan, Chie CRNA, o demons a ing calm mas e y and leade ship in anes hesia.
To D . Shane Mandalia, DO, o eaching dep h o hough and he cou age o ques ion.
To D . Ka en B. Domino, MD, o encou aging in ellec ual inqui y and challenging he no ms o
medicine.
To D . Ronald Pauldine, MD, o eminding me ha medicine begins wi h humani y be o e p o-
cedu e.
To D . G. Bu kha d Mackensen, MD, PhD, FASE, o ad ancing he on ie s o anes hesiology
wi h excellence and p ecision.
To he Paci ic No hwes Na ional Labo a o y (PNNL), o shaping my unde s anding o secu i y,
esponsibili y, and scien i ic pu pose.
To he Uni e si y o Washing on, and especially he UW Depa men o Anes hesiology and Pain
Medicine, whose en i onmen o clinical excellence and academic igo con inues o guide his
jou ney.
This wo k exis s because o hose who chose o each, p o ec , and belie e.
25
